© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Dupilumab Improves Asthma Control, HRQoL Regardless of Comorbid Th2 Inflammatory Disease
May 21, 2025
Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.
Johanna Finkle, MD, on Approaching Weight Loss Discussions with Reproductive-Aged Patients
May 21, 2025
ACOG 2025: Johanna Finkle, MD, shares strategies to start weight conversations with patients and build clinician confidence in counseling and treatment options.
FDA Narrows COVID-19 Vaccine Access to High-Risk Groups, Demands New Trials for Healthy Adults
May 21, 2025
The FDA's new approach to evaluating and approving COVID-19 vaccines will move the US away from a one-size-fits-all approach and closer to policy in other countries.
PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD
May 20, 2025
ACOG 2025: Elizabeth Mollard, PhD, discusses her research on how Medicaid policies influence postpartum depression screening rates.
Real-World Memory Clinic Data Suggest Lecanemab Use Is Feasible, Practical for Adults with Alzheimer Disease
May 20, 2025
Adults with early AD who were treated with lecanemab in a specialty memory clinic experienced adverse events comparable to those seen in clinical trials.
“I’m Just Tired”: Listening for the Words Patients Actually Use
May 20, 2025
ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.
Investigational Oral Medication for OSA Meets Primary Endpoints in Phase 3 Clinical Trial
May 20, 2025
The anti-apneic neuromuscular modulator AD109 targets the root cause of OSA by increasing upper airway muscle tone during sleep, according to Apnimed.
FDA Grants Novavax COVID-19 Vaccine Full Approval for High-Risk Groups
May 20, 2025
Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.
Laxmi Gannu, MS, Explains a New Study of Clinician's Knowledge of Post Partum Depression
May 19, 2025
ACOG 2025: The Junonia study was designed to understand gaps in care for women with PPD using surveys of their clinicians and care coordinators.
Nanette Santoro, MD, Highlights Findings on Fezolinetant From Pooled Analysis of Phase 3 Skylight Development Program Trials
May 19, 2025
The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.